{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:00:54Z","timestamp":1780592454653,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10384-022-00934-z","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T02:02:32Z","timestamp":1659146552000},"page":"434-439","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Newly or switching effect of a selective EP2 agonist on intraocular pressure in Japanese patients with open-angle glaucoma"],"prefix":"10.1007","volume":"66","author":[{"given":"Koji","family":"Ueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-1476","authenticated-orcid":false,"given":"Rei","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Honjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiroaki","family":"Shirato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"934_CR1","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901\u201311.","journal-title":"JAMA"},{"key":"934_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ophtha.2015.10.053","volume":"123","author":"BE Prum Jr","year":"2016","unstructured":"Prum BE Jr, Rosenberg LF, Gedde SJ, Mansberger SL, Stein JD, Moroi SE, et al. Primary open-angle glaucoma preferred practice pattern(\u00ae) guidelines. Ophthalmology. 2016;123:41\u2013111.","journal-title":"Ophthalmology"},{"key":"934_CR3","unstructured":"The Japan Glaucoma Society. Guidelines for Glaucoma (5th edition). Nippon Ganka Gakkai Zashi.  2022;126:85\u2013177."},{"key":"934_CR4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/08820538.2021.2003824","volume":"37","author":"R Sakata","year":"2022","unstructured":"Sakata R, Chang PY, Sung KR, Kim TW, Wang TH, Perera SA, et al. Prostaglandin-associated periorbitopathy syndrome (PAPS): addressing an unmet clinical need. Semin Ophthalmol. 2022;37:447\u201354.","journal-title":"Semin Ophthalmol"},{"key":"934_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10384-021-00844-6","volume":"65","author":"M Aihara","year":"2021","unstructured":"Aihara M. Prostanoid receptor agonists for glaucoma treatment. Jpn J Ophthalmol. 2021;65:581\u201390.","journal-title":"Jpn J Ophthalmol"},{"key":"934_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/00044011-200424060-00004","volume":"24","author":"P Denis","year":"2004","unstructured":"Denis P, Lafuma A, Berdeaux G. Medical outcomes of glaucoma therapy from a nationwide representative survey. Clin Drug Investig. 2004;24:343\u201352.","journal-title":"Clin Drug Investig"},{"key":"934_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1167\/iovs.17-22745","volume":"59","author":"T Kirihara","year":"2018","unstructured":"Kirihara T, Taniguchi T, Yamamura K, Iwamura R, Yoneda K, Odani-Kawabata N, et al. Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent. Invest Ophthalmol Vis Sci. 2018;59:145\u201353.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"934_CR8","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1089\/jop.2019.0044","volume":"35","author":"M Aihara","year":"2019","unstructured":"Aihara M, Lu F, Kawata H, Tanaka Y, Yamamura K, Odani-Kawabata N, et al. Pharmacokinetics, safety, and intraocular pressure-lowering profile of omidenepag isopropyl, a selective, nonprostaglandin, prostanoid EP2 receptor agonist, in healthy Japanese and caucasian volunteers (phase I study). J Ocul Pharm Ther. 2019;35:542\u201350.","journal-title":"J Ocul Pharm Ther"},{"key":"934_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/IJG.0000000000001221","volume":"28","author":"M Aihara","year":"2019","unstructured":"Aihara M, Lu F, Kawata H, Iwata A, Liu K, Odani-Kawabata N, et al. Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension. J Glaucoma. 2019;28:375\u201385.","journal-title":"J Glaucoma"},{"key":"934_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajo.2020.06.003","volume":"220","author":"M Aihara","year":"2020","unstructured":"Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N, Shams NK. Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the phase 3 AYAME study. Am J Ophthalmol. 2020;220:53\u201363.","journal-title":"Am J Ophthalmol"},{"key":"934_CR11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10384-021-00868-y","volume":"65","author":"M Aihara","year":"2021","unstructured":"Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study. Jpn J Ophthalmol. 2021;65:810\u201319.","journal-title":"Jpn J Ophthalmol"},{"key":"934_CR12","first-page":"1641","volume":"111","author":"A Iwase","year":"2004","unstructured":"Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641\u201348.","journal-title":"Ophthalmology"},{"key":"934_CR13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s10384-020-00748-x","volume":"64","author":"M Aihara","year":"2020","unstructured":"Aihara M, Ropo A, Lu F, Kawata H, Iwata A, Odani-Kawabata N, et al. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-\/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study. Jpn J Ophthalmol. 2020;64:398\u2013406.","journal-title":"Jpn J Ophthalmol"},{"key":"934_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1089\/jop.2019.0079","volume":"36","author":"Y Yamamoto","year":"2020","unstructured":"Yamamoto Y, Taniguchi T, Inazumi T, Iwamura R, Yoneda K, Odani-Kawabata N, et al. Effects of the selective EP2 receptor agonist omidenepag on adipocyte differentiation in 3T3-L1 cells. J Ocul Pharm Ther. 2020;36:162\u201369.","journal-title":"J Ocul Pharm Ther"},{"key":"934_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1089\/jop.2020.0003","volume":"36","author":"Y Esaki","year":"2020","unstructured":"Esaki Y, Katsuta O, Kamio H, Noto T, Mano H, Iwamura R, et al. The antiglaucoma agent and EP2 receptor agonist omidenepag does not affect eyelash growth in mice. J Ocul Pharm Ther. 2020;36:529\u201333.","journal-title":"J Ocul Pharm Ther"},{"key":"934_CR16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10384-021-00855-3","volume":"65","author":"R Sakata","year":"2021","unstructured":"Sakata R, Fujishiro T, Saito H, Nakamura N, Honjo M, Shirato S, et al. Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis. Jpn J Ophthalmol. 2021;65:591\u201397.","journal-title":"Jpn J Ophthalmol"},{"key":"934_CR17","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.2147\/OPTH.S271789","volume":"14","author":"K Inoue","year":"2020","unstructured":"Inoue K, Inoue J, Kunimatsu-Sanuki S, Nozaki N, Shimizu K, Ishida K, et al. Short-term efficacy and safety of omidenepag isopropyl in patients with normal-tension glaucoma. Clin Ophthalmol. 2020;14:2943\u201349.","journal-title":"Clin Ophthalmol"},{"key":"934_CR18","doi-asserted-by":"crossref","unstructured":"No authors listed. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:498\u2013505.","DOI":"10.1016\/S0002-9394(98)00272-4"},{"key":"934_CR19","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268\u201379.","journal-title":"Arch Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-022-00934-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-022-00934-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-022-00934-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T08:09:48Z","timestamp":1661414988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-022-00934-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1007\/s10384-022-00934-z","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]},"assertion":[{"value":"22 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K. Ueda, None; R. Sakata, Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events (Santen, Senju, Otsuka, Kowa), Participation on a Data Safety Monitoring Board or Advisory Board (Santen), Receipt of equipment, materials, drugs, medical writing, gifts or other services (Santen, Kowa); T. Fujishiro, None; M. Honjo, Grants or contracts from any entity (Santen, Alcon), Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events (Santen, Otsuka, Kowa, Novartis), Participation on a Data Safety Monitoring Board or Advisory Board (Santen), Receipt of equipment, materials, drugs, medical writing, gifts or other services (Santen, Kowa); S. Shiarto, Consulting fees (Santen, Otsuka, Senju, Kowa); M. Aihara, Grants or contracts from any entity (Santen, Alcon, Pfizer, Otsuka, Johnson & Johnson, TOMEY, CREWT Medical Systems, Senju, Novartis, Kowa, Wakamoto, Glaukos, Ono, Sato), Consulting fees (Santen, Alcon, Kowa, Wakamoto, Glaukos, Astellas, Senju, Pfizer, Otsuka, HOYA, IRIDEX Medical Systems), Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events (Santen, Senju, Alcon, Novartis, Pfizer, Kowa, Otsuka, Johnson & Johnson, HOYA, Glaukos, TOMEY, IRIDEX, CREWT Medical Systems, CANON, ZEISS, Sato), Participation on a Data Safety Monitoring Board or Advisory Board (Santen, Senju, HOYA, Kowa), Receipt of equipment, materials, drugs, medical writing, gifts or other services (Kowa, Santen).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}